{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05921760",
            "orgStudyIdInfo": {
                "id": "CL1-95031-006"
            },
            "secondaryIdInfos": [
                {
                    "id": "2023-503236-41",
                    "type": "EUDRACT_NUMBER"
                }
            ],
            "organization": {
                "fullName": "Servier",
                "class": "INDUSTRY"
            },
            "briefTitle": "Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma",
            "officialTitle": "A Phase 1/2, Safety Lead-in and Dose Expansion, Open-label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Activity of Ivosidenib in Combination With Nivolumab and Ipilimumab in Previously Treated Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "ivosidenib-nivolumab-and-ipilimumab-combination-in-previously-treated-subjects-with-nonresectable-or-metastatic-mutant-cholangiocarcinoma"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-10-23",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-03",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-03",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-04-21",
            "studyFirstSubmitQcDate": "2023-06-19",
            "studyFirstPostDateStruct": {
                "date": "2023-06-27",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-24",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-25",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Servier Bio-Innovation LLC",
                "class": "INDUSTRY"
            },
            "collaborators": [
                {
                    "name": "Institut de Recherches Internationales Servier",
                    "class": "OTHER"
                }
            ]
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a Phase 1/2 study evaluating the safety, tolerability, and activity of ivosidenib in combination with immunotherapy in participants with nonresectable or metastatic cholangiocarcinoma. The study includes two phases: the safety lead-in phase to determine the recommended combination dose (RCD) of ivosidenib in combination with immunotherapy and the dose expansion phase to assess the efficacy of ivosidenib in combination with immunotherapy. Study treatment will be administered until participant experiences unacceptable toxicity, disease progression, or other discontinuation criteria are met."
        },
        "conditionsModule": {
            "conditions": [
                "IDH1-mutant Cholangiocarcinoma"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 92,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Safety Lead-In Phase - ivosidenib",
                    "type": "EXPERIMENTAL",
                    "description": "First phase of the study.",
                    "interventionNames": [
                        "Drug: Ivosidenib",
                        "Drug: Nivolumab",
                        "Drug: Ipilimumab"
                    ]
                },
                {
                    "label": "Experimental Phase - Cohort 1",
                    "type": "EXPERIMENTAL",
                    "description": "Second phase of the study. Cohort 1 will include the anti-PD1/L1-na\u00efve subpopulation.",
                    "interventionNames": [
                        "Drug: Recommended Combination Dose (RCD) of ivosidenib",
                        "Drug: Nivolumab",
                        "Drug: Ipilimumab"
                    ]
                },
                {
                    "label": "Experimental Phase - Cohort 2",
                    "type": "EXPERIMENTAL",
                    "description": "Second phase of the study. Cohort 2 will include the anti-PD1/L1 previously treated subpopulation.",
                    "interventionNames": [
                        "Drug: Recommended Combination Dose (RCD) of ivosidenib",
                        "Drug: Nivolumab",
                        "Drug: Ipilimumab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Ivosidenib",
                    "description": "ivosidenib taken once daily",
                    "armGroupLabels": [
                        "Safety Lead-In Phase - ivosidenib"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Recommended Combination Dose (RCD) of ivosidenib",
                    "description": "The RCD of ivosidenib taken once daily",
                    "armGroupLabels": [
                        "Experimental Phase - Cohort 1",
                        "Experimental Phase - Cohort 2"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Nivolumab",
                    "description": "Nivolumab taken by intravenous infusion",
                    "armGroupLabels": [
                        "Experimental Phase - Cohort 1",
                        "Experimental Phase - Cohort 2",
                        "Safety Lead-In Phase - ivosidenib"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Ipilimumab",
                    "description": "Ipilimumab taken by intravenous infusion",
                    "armGroupLabels": [
                        "Experimental Phase - Cohort 1",
                        "Experimental Phase - Cohort 2",
                        "Safety Lead-In Phase - ivosidenib"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Safety Phase: Number of dose limiting toxicities (DLTs) associated with study drug regimen, during the first 2 cycles of treatment",
                    "description": "Occurring during the safety lead-in phase",
                    "timeFrame": "Through the end of Cycle 2, day 42 (Cycle 1 and 2 are each 21 days)"
                },
                {
                    "measure": "Safety Phase: To determine the recommended combination dose (RDC) of ivosidenib in combination of immunotherapy",
                    "description": "Occurring during the safety lead-in phase",
                    "timeFrame": "Through the end of Cycle 2, day 42 (Cycle 1 and 2 are each 21 days)"
                },
                {
                    "measure": "Expansion Phase: To assess the Objective Response (confirmed complete response [CR] or confirmed partial response [PR]) of antitumor activity using RECIST v1.1)",
                    "description": "To assess the Objective Response (confirmed complete response \\[CR\\] or confirmed partial response \\[PR\\]) of antitumor activity using RECIST v1.1)",
                    "timeFrame": "up to 3 years"
                },
                {
                    "measure": "Safety Phase: Number of Adverse Events (AEs)",
                    "description": "Occurring during the safety lead-in phase",
                    "timeFrame": "Up to 3 years"
                },
                {
                    "measure": "Safety Phase: Number of Adverse Events of Special Interests (AESIs)",
                    "description": "Occurring during the safety lead-in phase",
                    "timeFrame": "Up to 3 years"
                },
                {
                    "measure": "Safety Phase: Number of Serious Adverse Events (SAEs)",
                    "description": "Occurring during the safety lead-in phase",
                    "timeFrame": "Up to 3 years"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Safety Phase: area under the concentration-vs-time curve (AUC) from 0 to time of last measurable concentration (AUC0-t)",
                    "description": "Occurring during the safety lead-in phase",
                    "timeFrame": "Up to 3 years"
                },
                {
                    "measure": "Safety Phase: Plasma 2-hydroxyglutarate (2-HG) concentration",
                    "description": "Occurring during the safety lead-in phase",
                    "timeFrame": "up to 3 years"
                },
                {
                    "measure": "Expansion Phase: Number of Adverse Events (AEs)",
                    "description": "Occurring during the expansion phase",
                    "timeFrame": "Up to 3 years"
                },
                {
                    "measure": "Expansion Phase: Duration of response (DOR)",
                    "description": "Occurring during the expansion phase",
                    "timeFrame": "up to 3 years"
                },
                {
                    "measure": "Expansion Phase: progression-free survival (PFS)",
                    "description": "Occurring during the expansion phase",
                    "timeFrame": "up to 3 years"
                },
                {
                    "measure": "Expansion Phase: disease control (DC) (complete response-CR, partial response-PR, or stable disease-SD)",
                    "description": "Occurring during the expansion phase",
                    "timeFrame": "up to 3 years"
                },
                {
                    "measure": "Expansion Phase: time to response (TTR) according to RECIST v1.1",
                    "description": "Occurring during the expansion phase",
                    "timeFrame": "up to 3 years"
                },
                {
                    "measure": "Expansion Phase: Overall survival (OS)",
                    "description": "Occurring during the expansion phase",
                    "timeFrame": "up to 3 years"
                },
                {
                    "measure": "Expansion Phase : area under the concentration-vs-time curve (AUC) from 0 to time of last measurable concentration (AUC0-t)",
                    "description": "Occurring during the expansion phase",
                    "timeFrame": "Up to 3 years"
                },
                {
                    "measure": "Expansion Phase: Plasma 2-hydroxygluturate (2-HG) concentration",
                    "description": "Occurring during the expansion phase",
                    "timeFrame": "up to 3 years"
                },
                {
                    "measure": "Safety Phase: AUC over 1 dosing interval at steady state (AUCtau,ss)",
                    "description": "Occurring during the safety lead-in phase",
                    "timeFrame": "Up to 3 years"
                },
                {
                    "measure": "Safety Phase: time to maximum concentration (Tmax)",
                    "description": "Occurring during the safety lead-in phase",
                    "timeFrame": "Up to 3 years"
                },
                {
                    "measure": "Safety Phase: maximum concentration (Cmax)",
                    "description": "Occurring during the safety lead-in phase",
                    "timeFrame": "Up to 3 years"
                },
                {
                    "measure": "Safety Phase: trough concentration (Ctrough)",
                    "description": "Occurring during the safety lead-in phase",
                    "timeFrame": "Up to 3 years"
                },
                {
                    "measure": "Safety Phase: apparent volume of distribution (Vd/F)",
                    "description": "Occurring during the safety lead-in phase",
                    "timeFrame": "Up to 3 years"
                },
                {
                    "measure": "Safety Phase: apparent clearance (CL/F)",
                    "description": "Occurring during the safety lead-in phase",
                    "timeFrame": "Up to 3 years"
                },
                {
                    "measure": "Expansion Phase: Number of Adverse Events of Special Interests (AESIs)",
                    "description": "Occurring during the expansion phase",
                    "timeFrame": "Up to 3 years"
                },
                {
                    "measure": "Expansion Phase: Number of Serious Adverse Events (SAEs)",
                    "description": "Occurring during the expansion phase",
                    "timeFrame": "Up to 3 years"
                },
                {
                    "measure": "Expansion Phase: AUC over 1 dosing interval at steady state (AUCtau,ss)",
                    "description": "Occurring during the expansion phase",
                    "timeFrame": "Up to 3 years"
                },
                {
                    "measure": "Expansion Phase: time to maximum concentration (Tmax)",
                    "description": "Occurring during the expansion phase",
                    "timeFrame": "Up to 3 years"
                },
                {
                    "measure": "Expansion Phase: maximum concentration (Cmax)",
                    "description": "Occurring during the expansion phase",
                    "timeFrame": "Up to 3 years"
                },
                {
                    "measure": "Expansion Phase: trough concentration (Ctrough)",
                    "description": "Occurring during the expansion phase",
                    "timeFrame": "Up to 3 years"
                },
                {
                    "measure": "Expansion Phase: apparent volume of distribution (Vd/F)",
                    "description": "Occurring during the expansion phase",
                    "timeFrame": "Up to 3 years"
                },
                {
                    "measure": "Expansion Phase: apparent clearance (CL/F)",
                    "description": "Occurring during the expansion phase",
                    "timeFrame": "Up to 3 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Male of female participant age \u2265 18 years old\n* Have documented IDH1 gene-mutated disease based on local testing procedure (R132C/L/G/H/S mutations variants tested)\n* Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 or 1\n* Has a histopathological diagnosis consistent with nonresectable or metastatic cholangiocarcinoma and are not eligible for curative resection, transplantation, or ablative therapies\n* Participants must have at least one measurable lesion as defined by RECIST Version 1.1. Subjects who have received prior local therapy (including but not limited to embolization, chemoembolization, radiofrequency ablation, or radiation therapy) are eligible provided measurable disease falls outside of the treatment field or if within the field but has shown \u2265 20% growth in size post-treatment assessment.\n\nExclusion Criteria:\n\n* Received prior treatment with an IDH inhibitor or prior treatment with an immune checkpoint inhibitor other than anti-PD1/L1\n* Have active autoimmune disease or any condition requiring systemic treatment with either corticosteroids (\\> 10 mg daily of prednisone equivalents) or other immunosuppressive medications within 14 days of study treatment\n* Participants who have not recovered from toxicity of previous anticancer therapy, including Grade \u2265 1 non-hematologic toxicity, according to the National Cancer Institute Common Terminology Criteria for Adverse Events v5.0, prior to the first IMP administration. Residual Grade \u2264 2 toxicity from chemotherapy (e.g., alopecia, neuropathy) may be allowed.\n* Have known symptomatic brain metastases requiring steroids. Subjects with previously diagnosed brain metastases are eligible if they have completed their treatment and have recovered from the acute effects of radiation therapy or surgery prior to study entry, have discontinued corticosteroid treatment for these metastases for at least 4 weeks, and have radiographically stable disease for at least 3 months prior to study entry. Note: Up to 10 mg per day of prednisone equivalent will be allowed.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Institut de Recherches Internationales Servier",
                    "role": "CONTACT",
                    "phone": "+33 1 55 72 60-00",
                    "email": "scientificinformation@servier.com"
                }
            ],
            "locations": [
                {
                    "facility": "Mayo Clinic",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Scottsdale",
                    "state": "Arizona",
                    "zip": "85259",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.50921,
                        "lon": -111.89903
                    }
                },
                {
                    "facility": "The University of Arizona Cancer Center (Uacc)",
                    "status": "WITHDRAWN",
                    "city": "Tucson",
                    "state": "Arizona",
                    "zip": "85719-1478",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 32.22174,
                        "lon": -110.92648
                    }
                },
                {
                    "facility": "UCSF - Medical Center at Mission Bay",
                    "status": "RECRUITING",
                    "city": "San Francisco",
                    "state": "California",
                    "zip": "94158",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 37.77493,
                        "lon": -122.41942
                    }
                },
                {
                    "facility": "Ucsf Helen Diller Family Comprehensive Cancer Center",
                    "status": "RECRUITING",
                    "city": "San Francisco",
                    "state": "California",
                    "zip": "94158",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 37.77493,
                        "lon": -122.41942
                    }
                },
                {
                    "facility": "Mayo Clinic - Jacksonville, Fl",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Jacksonville",
                    "state": "Florida",
                    "zip": "32224",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 30.33218,
                        "lon": -81.65565
                    }
                },
                {
                    "facility": "Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins",
                    "status": "RECRUITING",
                    "city": "Baltimore",
                    "state": "Maryland",
                    "zip": "21231",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.29038,
                        "lon": -76.61219
                    }
                },
                {
                    "facility": "Massachusetts General Hospital",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02114",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "Dana Farber Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02215",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "The University of Michigan Rogel Cancer Center",
                    "status": "RECRUITING",
                    "city": "Ann Arbor",
                    "state": "Michigan",
                    "zip": "48109-2800",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.27756,
                        "lon": -83.74088
                    }
                },
                {
                    "facility": "Mayo Clinic - Rochester, Mn",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Rochester",
                    "state": "Minnesota",
                    "zip": "55905",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 44.02163,
                        "lon": -92.4699
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Cancer Center",
                    "status": "NOT_YET_RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10065",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Sarah Cannon Research Institute",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37203",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "The University of Texas Md Anderson Cancer Center",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "Clatterbridge Hospital",
                    "status": "WITHDRAWN",
                    "city": "Bebington",
                    "zip": "L63 4JY",
                    "country": "United Kingdom",
                    "geoPoint": {
                        "lat": 53.35,
                        "lon": -3.01667
                    }
                },
                {
                    "facility": "UCLH",
                    "status": "RECRUITING",
                    "city": "London",
                    "zip": "NW1 2PG",
                    "country": "United Kingdom",
                    "geoPoint": {
                        "lat": 51.50853,
                        "lon": -0.12574
                    }
                },
                {
                    "facility": "Christie Hospital",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Manchester",
                    "zip": "M20 4BX",
                    "country": "United Kingdom",
                    "geoPoint": {
                        "lat": 53.48095,
                        "lon": -2.23743
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "type": "BACKGROUND",
                    "citation": "Kelley RK, Cleary JM, Sahai V, Baretti M, Bridgewater JA, Hua Z, Gliser C, Bian Y, Abou-Alfa GK. A phase 1/2, safety lead-in and dose expansion, open-label, multicenter trial investigating the safety, tolerability, and preliminary activity of ivosidenib in combination with nivolumab and ipilimumab in previously treated subjects with IDH1-mutated nonresectable or metastatic cholangiocarcinoma. J Clin Oncol. 2024 May 29;42(16_Supplement):TPS4197. doi: https://doi.org/10.1200/JCO.2024.42.16_suppl.TPS4197"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "Qualified scientific and medical researchers can request access to anonymized patient-level and study-level clinical trial data.\n\nAccess can be requested for all interventional clinical studies:\n\n* used for Marketing Authorization (MA) of medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).\n* where Servier is the Marketing Authorization Holder (MAH). The date of the first MA of the new medicine (or the new indication) in one of the EEA Member States will be considered for this scope.\n\nIn addition, access can be requested for all interventional clinical studies in patients:\n\n* sponsored by Servier\n* with a first patient enrolled as of 1 January 2004 onwards\n* for New Chemical Entity or New Biological Entity (new pharmaceutical form excluded) for which development has been terminated before any Marketing authorization (MA) approval.",
            "infoTypes": [
                "STUDY_PROTOCOL",
                "SAP",
                "ICF",
                "CSR"
            ],
            "timeFrame": "After Marketing Authorization in EEA or US if the study is used for the approval.",
            "accessCriteria": "Researchers should register on Servier Data Portal and fill in the research proposal form. This form in four parts should be fully documented. The Research Proposal Form will not be reviewed until all mandatory fields are completed.",
            "url": "http://clinicaltrials.servier.com/"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000018281",
                    "term": "Cholangiocarcinoma"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000230",
                    "term": "Adenocarcinoma"
                },
                {
                    "id": "D000002277",
                    "term": "Carcinoma"
                },
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M20426",
                    "name": "Cholangiocarcinoma",
                    "asFound": "Cholangiocarcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M3585",
                    "name": "Adenocarcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "T755",
                    "name": "Bile Duct Cancer",
                    "asFound": "Cholangiocarcinoma",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000077594",
                    "term": "Nivolumab"
                },
                {
                    "id": "D000074324",
                    "term": "Ipilimumab"
                },
                {
                    "id": "C000627630",
                    "term": "Ivosidenib"
                },
                {
                    "id": "D000005998",
                    "term": "Glycine"
                }
            ],
            "ancestors": [
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000082082",
                    "term": "Immune Checkpoint Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000018684",
                    "term": "Glycine Agents"
                },
                {
                    "id": "D000018377",
                    "term": "Neurotransmitter Agents"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M1854",
                    "name": "Nivolumab",
                    "asFound": "Technique",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1348",
                    "name": "Ipilimumab",
                    "asFound": "Enrolled",
                    "relevance": "HIGH"
                },
                {
                    "id": "M242252",
                    "name": "Ivosidenib",
                    "asFound": "Work-up",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9104",
                    "name": "Glycine",
                    "asFound": "Work-up",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                },
                {
                    "id": "M2342",
                    "name": "Immune Checkpoint Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20504",
                    "name": "Neurotransmitter Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "T7",
                    "name": "Glycine",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "AA",
                    "name": "Amino Acids"
                }
            ]
        }
    },
    "hasResults": false
}